In a release dated 14 September 2026, Silex Systems Limited (ASX:SLX) (OTCQX: SILXY) reported the execution of the agreement between GLE and Cameco. Silex is a technology commercialisation company whose primary asset is the SILEX laser enrichment technology, originally developed at its Facility in Sydney. GLE is the exclusive licensee of that technology for uranium enrichment.

This article outlines the contents of the announcement, the sector context, the risks that the company identifies and the next steps indicated in the release.

Press Release Details

Under the exclusive offtake agreement, Cameco will buy all of the future production of the planned Paducah Laser Enrichment Facility (PLEF). Silex Managing Director and CEO Michael Goldsworthy said the agreement provides a home for all of GLE’s future nuclear fuel products, including natural UF6 and enriched uranium products.

On pricing, the company said the agreement will provide GLE with pricing for its products equivalent to Cameco’s average realised price, net of appropriate selling costs, achieved on an annual basis across its long-term contracting portfolio. Silex noted that this arrangement avoids the significant cost of GLE establishing its own sales and Marketing resources.

The release describes Cameco as one of the largest global providers of nuclear fuel, with investments across the nuclear industry, including 49 per cent ownership interests in both GLE and Westinghouse Electric Company. Mr Goldsworthy said the agreement also provides a key commercial pillar to support a future final Investment decision (FID) for the PLEF and that it contains customary contractual terms intended to protect the interests of GLE and Silex.

Silex stated that, subject to several factors, the SILEX technology could become a major contributor to nuclear fuel production for current and future reactor fleets. The factors named in the release are industry and government support, a feasibility assessment for the PLEF leading to a positive FID, and supportive market conditions. The potential product range includes natural grade uranium as UF6, Low Enriched Uranium (LEU), LEU+ and high-assay LEU (HALEU) for next-generation advanced reactors, including small modular reactors.

The announcement was authorised for release by the Silex Board of Directors. The release does not disclose financial terms such as volumes, contract duration or a quantified price, beyond the pricing mechanism described above.

In its background section, Silex also refers to other applications of the SILEX technology. These include the Quantum Silicon (Q-Si) project, which targets enriched silicon for silicon-based quantum computing, and an early-stage Stable Isotope Project (SIP) focused on isotopes required for semiconductor and medical applications.

Sector Backdrop

Uranium enrichment is a stage of the nuclear fuel cycle in which the proportion of the fissile isotope is increased so that uranium can be used in reactors. Natural uranium is converted to UF6 before enrichment, and different reactor designs require different enrichment levels. LEU is used in most existing commercial reactors, while HALEU is associated with several advanced reactor designs under development.

The Silex release refers to the world’s rapidly growing nuclear reactor fleet and to next-generation advanced reactors, including small modular reactors. Enrichment capacity and fuel Supply chains have been a subject of attention among governments and utilities, and the release notes that US government funding initiatives and policy settings are relevant to its projects.

Offtake agreements are common in fuel supply, as producers often secure contracted buyers ahead of committing Capital to new capacity. In this case, the agreement links the PLEF to Cameco’s existing contracting portfolio rather than to a fixed price, as described in the announcement.

Risks Shareholders Should Weigh

Silex states that the commercial future of the SILEX technology in uranium, silicon, stable and other isotopes is uncertain and that any plans for commercial deployment are speculative. The success of the technology development program and the proposed Paducah project remains subject to several factors, including satisfactory completion of the SILEX technology maturation program, nuclear fuel market conditions, industry and government support, project feasibility and commercial plant licensing.

The offtake agreement does not itself constitute an FID. The release refers to a feasibility assessment for the PLEF that would need to lead to a positive FID, and to the agreement being a commercial pillar for that decision rather than a commitment to build.

The risk factors listed in the announcement include economic stresses such as interest rates and inflation, tariffs including those imposed by the United States, geopolitical risks including Russia’s invasion of Ukraine, the war between Iran and the US and tensions between China and Taiwan, and the effects of climate change and mitigation efforts. Other items include market Demand for natural and enriched uranium, competition from alternative technologies, regulatory changes related to US Government funding initiatives, potential third-party claims against Silex’s intellectual property, and actions taken by commercialisation partners and other stakeholders.

The release also states that its contents should not be considered investment, legal or tax advice and that forward-looking statements are subject to change.

What’s Next

The announcement indicates that the next step for the PLEF is a feasibility assessment leading to a possible FID, subject to industry and government support and market conditions. No date for the assessment or the FID is given in the release.

Silex has said it will continue to provide information on its activities through its website and ASX announcements, and the company notes that it is not obliged to update forward-looking statements except where required by law or the ASX Listing Rules.